Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II fotemustine + dexamethasone in refractory or relapsing multiple myeloma
2008-001175-29Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fotemustine in multiple myeloma (MM), sponsored by IRCCS San Matteo Foundation. Primary endpoint: haematological and extrahaematological toxicity. Started Mar 2008; status: terminated.
02
Drugs
fotemustine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-001175-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001175-29.